12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
In a Memorandum issued this week, OFCCP has granted a three-month, national interest exemption and w...
Read More >
The Federal Trade Commission (FTC) has announced its annual revisions to the thresholds under the Ha...
Read More >
Report on Supply Chain Compliance 2, no. 20 (October 24, 2019) - When the United States Customs and...
Read More >
Just when you thought the regulators had forgotten about HVCRE ADC, they issued a new notice of prop...
Read More >
Financial Services Company Disciplined a Black Employee for Complaining About Discrimination, Agency...
Read More >
California Governor Gavin Newsom on Aug. 30 signed into law a bill that extends the deadline for sma...
Read More >